Mayflower Financial Advisors LLC Buys 3,414 Shares of AbbVie Inc. $ABBV

Mayflower Financial Advisors LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 21.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,098 shares of the company’s stock after purchasing an additional 3,414 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in AbbVie were worth $4,422,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new stake in AbbVie in the 2nd quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC boosted its holdings in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after acquiring an additional 5,675,095 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after acquiring an additional 3,666,521 shares during the period. Vanguard Group Inc. increased its holdings in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of AbbVie during the second quarter valued at approximately $581,817,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Up 0.1%

NYSE:ABBV opened at $230.07 on Monday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a 50-day moving average price of $226.73 and a two-hundred day moving average price of $212.72. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The firm has a market cap of $406.63 billion, a price-to-earnings ratio of 174.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ABBV shares. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Morgan Stanley lifted their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Bank of America increased their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.